Beyond the Burden: Surgical Innovations That Lengthen Treatment Intervals in Retinal Vascular Diseases

Author(s)/Faculty: Carl D. Regillo, MD, FACS; Margaret A. Chang, MD, MS; Veeral Sheth, MD, MBA, FASRS
Release Date: 9/16/2022Expiration Date: 9/15/2023
Credit Type: CMENumber of Credits: 1.25
Content Type: LectureProvider:
Reducing treatment burden in patients receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for the management of retinal vascular diseases is imperative to address suboptimal outcomes through loss of patient adherence due to frequent dosing schedules. Refinement of treatment protocols have aimed to address this unmet need, yet most patients still require frequent dosing to maintain initial visual acuity gains. To address treatment burden, novel delivery systems have been developed that reduce the need for frequent dosing but require unique surgical approaches at the initiation of their use to achieve optimal efficacy and safety outcomes. Gene therapy is currently being evaluated in ongoing clinical studies, while the FDA-approved Port Delivery System (PDS) with ranibizumab has demonstrated maintenance of visual acuity gains with extended treatment intervals out to 6 months. In this CME activity, experts in the field will evaluate the evidence pertaining to new surgical innovations that can enhance outcomes by reducing treatment burden in patients with retinal vascular diseases, as well as provide guidance for best practices that can reduce the potential for complications when utilizing the PDS with ranibizumab or subretinal gene therapy for the management of patients with neovascular age-related macular degeneration (nAMD).